199 related articles for article (PubMed ID: 15178763)
1. Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation.
Ganesh VK; Smith SA; Kotwal GJ; Murthy KH
Proc Natl Acad Sci U S A; 2004 Jun; 101(24):8924-9. PubMed ID: 15178763
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b.
Bernet J; Mullick J; Panse Y; Parab PB; Sahu A
J Virol; 2004 Sep; 78(17):9446-57. PubMed ID: 15308738
[TBL] [Abstract][Full Text] [Related]
3. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
4. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.
Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S
J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127
[TBL] [Abstract][Full Text] [Related]
5. Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein.
Isaacs SN; Argyropoulos E; Sfyroera G; Mohammad S; Lambris JD
J Virol; 2003 Aug; 77(15):8256-62. PubMed ID: 12857894
[TBL] [Abstract][Full Text] [Related]
6. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation.
Liszewski MK; Leung MK; Hauhart R; Buller RM; Bertram P; Wang X; Rosengard AM; Kotwal GJ; Atkinson JP
J Immunol; 2006 Mar; 176(6):3725-34. PubMed ID: 16517741
[TBL] [Abstract][Full Text] [Related]
7. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense.
Smith SA; Mullin NP; Parkinson J; Shchelkunov SN; Totmenin AV; Loparev VN; Srisatjaluk R; Reynolds DN; Keeling KL; Justus DE; Barlow PN; Kotwal GJ
J Virol; 2000 Jun; 74(12):5659-66. PubMed ID: 10823874
[TBL] [Abstract][Full Text] [Related]
8. Identification of complement regulatory domains in vaccinia virus complement control protein.
Mullick J; Bernet J; Panse Y; Hallihosur S; Singh AK; Sahu A
J Virol; 2005 Oct; 79(19):12382-93. PubMed ID: 16160165
[TBL] [Abstract][Full Text] [Related]
9. A new map of glycosaminoglycan and C3b binding sites on factor H.
Schmidt CQ; Herbert AP; Kavanagh D; Gandy C; Fenton CJ; Blaum BS; Lyon M; Uhrín D; Barlow PN
J Immunol; 2008 Aug; 181(4):2610-9. PubMed ID: 18684951
[TBL] [Abstract][Full Text] [Related]
10. Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.
Meseda CA; Kuhn J; Atukorale V; Campbell J; Weir JP
Clin Vaccine Immunol; 2014 Sep; 21(9):1330-8. PubMed ID: 25030055
[TBL] [Abstract][Full Text] [Related]
11. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
[TBL] [Abstract][Full Text] [Related]
12. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
[TBL] [Abstract][Full Text] [Related]
13. Domain swapping reveals complement control protein modules critical for imparting cofactor and decay-accelerating activities in vaccinia virus complement control protein.
Ahmad M; Raut S; Pyaram K; Kamble A; Mullick J; Sahu A
J Immunol; 2010 Nov; 185(10):6128-37. PubMed ID: 20956343
[TBL] [Abstract][Full Text] [Related]
14. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome.
Jokiranta TS; Jaakola VP; Lehtinen MJ; Pärepalo M; Meri S; Goldman A
EMBO J; 2006 Apr; 25(8):1784-94. PubMed ID: 16601698
[TBL] [Abstract][Full Text] [Related]
15. Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation.
Yadav VN; Pyaram K; Mullick J; Sahu A
J Virol; 2008 Apr; 82(7):3283-94. PubMed ID: 18216095
[TBL] [Abstract][Full Text] [Related]
16. Humanized recombinant vaccinia virus complement control protein (hrVCP) with three amino acid changes, H98Y, E102K, and E120K creating an additional putative heparin binding site, is 100-fold more active than rVCP in blocking both classical and alternative complement pathways.
Ghebremariam YT; Odunuga OO; Janse K; Kotwal GJ
Ann N Y Acad Sci; 2005 Nov; 1056():113-22. PubMed ID: 16387681
[TBL] [Abstract][Full Text] [Related]
17. Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance.
Smith SA; Sreenivasan R; Krishnasamy G; Judge KW; Murthy KH; Arjunwadkar SJ; Pugh DR; Kotwal GJ
Biochim Biophys Acta; 2003 Aug; 1650(1-2):30-9. PubMed ID: 12922167
[TBL] [Abstract][Full Text] [Related]
18. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
Loeven MA; Maciej-Hulme ML; Yanginlar C; Hubers MC; Kellenbach E; de Graaf M; van Kuppevelt TH; Wetzels J; Rabelink TJ; Smith RJH; van der Vlag J
Front Immunol; 2021; 12():676662. PubMed ID: 34489931
[TBL] [Abstract][Full Text] [Related]
19. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d.
Bhattacharjee A; Lehtinen MJ; Kajander T; Goldman A; Jokiranta TS
Mol Immunol; 2010 May; 47(9):1686-91. PubMed ID: 20378178
[TBL] [Abstract][Full Text] [Related]
20. Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.
Kumar J; Yadav VN; Phulera S; Kamble A; Gautam AK; Panwar HS; Sahu A
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
